COMBINE2: A Network Prospective 2DR Cohort Epidemiology Study

• Research type

  Research Study

• Full title

  ‘COMBINE-2’: Real-world evidence for effectiveness of Two Drug Regimen, Antiretroviral therapy with integrase inhibitors plus a reverse transcriptase inhibitor

• IRAS ID

  257169

• Contact name

  Margaret Johnson

• Contact email

  margaret.johnson1@nhs.net

• Sponsor organisation

  President of the NEAT ID Foundation

• Duration of Study in the UK

  3 years, 0 months, 1 days

• Research summary

  Gathering real-world evidence to evaluate effectiveness of a two drug-regimen (a treatment option that involves taking two drugs at the same time). The study will assess an integrase inhibitor such as DTG, being taken with a reverse transcriptase inhibitor such as Lamivudine (3TC) or Rilpivirine (RPV).

• REC name

  Yorkshire & The Humber - Bradford Leeds Research Ethics Committee

• REC reference

  19/YH/0087

• Date of REC Opinion

  15 Mar 2019

• REC opinion

  Unfavourable Opinion